Skip to content
DataLookout
Menu

The Treat-JIANCT07904780

Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Secondary endpoints revised (8)
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Proportion of disease flare
Timeframe: 4, 8 and 12 months

Secondary (8)

Time to disease flare
Time to regain inactive disease after flare
Incidence of adverse events, serious adverse events and suspected unexpected serious adverse reactions
Physician global assessment of disease activity
Patient's/parent's global assessment of well-being
Show 3 moreShow less
Active joint count
Erythrocyte sedimentation rate (ESR)
Childhood Health Assessment Questionnaire (CHAQ)

Arms and interventions

Stable TNF-inhibitor monotherapyActive comparator

Continued TNF-inhibitor therapy at a stable dose. This can be adalimumab, etanercept or golimumab.

TNF-inhibitor withdrawalExperimental

Doubled treatment interval of the TNF-inhibitor therapy for 4 months, then subsequent withdraw of the TNF-inhibitor therapy.

Drugs: Adalimumab, Etanercept, Golimumab

Sites

3 sites in 1 country